Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) unveiled its Q1 2026 financial results, reporting global net revenues of $15.002 billion, marking a 12.4% increase on a reported basis (10.3% operationally). Despite a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses, the company's adjusted diluted EPS exceeded internal expectations.

This robust performance has led to an upward revision of full-year 2026 adjusted diluted EPS guidance to $14.08–$14.28. Allergan Aesthetics, a subsidiary of AbbVie, announced on July 17 that Boey (trenibotulinumtoxinE) received approval across all 30 European Economic Area countries, making it the first and only rapid-onset, short-duration botulinum neurotoxin serotype E in Europe.

This approval follows an earlier Canadian approval, expanding AbbVie's high-margin aesthetic portfolio. Analysts have become increasingly positive, with Canaccord raising its price target to $282 from $273 while maintaining a Buy rating. The company's post-Humira growth engine, driven by flagship immunology assets Skyrizi and Rinvoq, generated $4.483 billion and $2.119 billion in Q1 net revenues, respectively.

Strong cash flow generation and pipeline expansion through M&A and R&D further bolster AbbVie's growth prospects. However, concerns remain about its elevated debt levels, legacy product erosion due to Humira's revenue drop, and persistent net margin challenges. Institutional investors have shown growing confidence, with 87 funds holding positions in AbbVie as of Q1 2026, up from 84 funds in Q4 2025.